This synergistic effect was linked to the suppression of Wnt/β-catenin signaling, suggesting that the EZH2–PPAR axis could serve as a potential therapeutic target in pancreatic cancer (Hu et al. 2021). This evidence concerns the gene EZH2 and familial pancreatic carcinoma.